Multiple Myeloma is a cancer that starts in the cells that make antibodies and grows in the bone marrow. Even after a high‑dose treatment called autologous hematopoietic stem cell transplantation, some patients still have a very small amount of disease that can be found with special laboratory tests, known as minimal residual disease. The study looks at people whose disease is still detectable after this transplant.
One group of participants receives two new medicines, teclistamab and talquetamab, which are given as injections under the skin. The other group receives the already‑approved drug daratumumab, also given by injection, together with the oral pill lenalidomide. All participants continue the assigned therapy for about a year while being checked regularly.
The purpose of the study is to see which maintenance approach is better at achieving a state where no disease can be detected and the patient has a complete response after 12 months. Participants visit the clinic at scheduled intervals for injections, take oral medication as directed, and undergo blood tests and occasional bone‑marrow examinations to determine if the cancer has become undetectable and to monitor safety.
Poland 
